T-cell responses of vaccinated cancer patients
- 8 February 2003
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 15 (2) , 131-137
- https://doi.org/10.1016/s0952-7915(03)00009-8
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18Tissue Antigens, 2002
- Escaping High Viral Load ExhaustionThe Journal of Experimental Medicine, 2002
- Estimating the Precursor Frequency of Naive Antigen-specific CD8 T CellsThe Journal of Experimental Medicine, 2002
- In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cellsEuropean Journal of Immunology, 2002
- Peptide‐specific CD8+ T‐cell evolution in vivo: Response to peptide vaccination with Melan‐A/MART‐1International Journal of Cancer, 2002
- Thymic Selection Generates a Large T Cell Pool Recognizing a Self-Peptide in HumansThe Journal of Experimental Medicine, 2002
- Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patientsInternational Journal of Cancer, 2001
- Enrichment and detection of live antigen-specific CD4+ and CD8+ T cells based on cytokine secretionEuropean Journal of Immunology, 1999
- Idiotypic protein-pulsed dendritic cell vaccination in multiple myelomaInternational Journal of Cancer, 1999
- Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancerInternational Journal of Cancer, 1998